Company intelligence / Profile preview

Benecyte Inc.

Durham, North Carolina, United States of Americadirectory.ncbiotech.org ↗

Ownership: Private
Development stage: Phase 2

Overview

Benecyte’s lead asset, CMN‑005, a CAR-CIK CD19 therapy, has advanced to Phase II clinical trials for follicular lymphoma and splenic marginal zone B-cell lymphoma. The company also develops additional immunotherapies targeting both hematologic cancers and solid tumors using its proprietary allogeneic CIK platform.[2][4]

Therapeutic areas: Oncology
Modalities: Allogeneic cytokine-induced killer (CIK) cells[2][3]Autologous RNA-loaded dendritic cells[2]CAR-CIK cell therapies (including CARCIK-CD19)[2]
Industry: Biotech

Drug pipeline

3 assets

CMN-005

Phase 2

Indications: B-cell acute lymphocytic leukemia, Chronic lymphocytic leukemia, Non-Hodgkin lymphoma

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Benecyte Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Benecyte Inc..

Explore the full profile